ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In part, this was also accomplished by the low-dose synergistic effect of countering different biological signaling pathways, with the goal of achieving short-term BCR–ABL1 kinase inhibition that resulted in induction of apoptosis in BCR–ABL1-positive and primary CML progenitor cells.